An artificial-intelligence approach created at Carolina could help bring new drugs to patients quicker.
An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.
The system is called Reinforcement Learning for Structural Evolution, known as ReLeaSE, and is an algorithm and computer program that comprises two neural networks which can be thought of as a teacher and a student. The teacher knows the syntax and linguistic rules behind the vocabulary of chemical structures for about 1.7 million known biologically active molecules. By working with the teacher, the student learns over time and becomes better at proposing molecules that are likely to be useful as new medicines.
Alexander Tropsha, Olexandr Isayev and Mariya Popova, all of the UNC Eshelman School of Pharmacy, are the creators of ReLeaSE. The University has applied for a patent for the technology, and the team published a proof-of-concept study in the journal Science Advances last week.
“If we compare this process to learning a language, then after the student learns the molecular alphabet and the rules of the language, they can create new ‘words,’ or molecules,” said Tropsha. “If the new molecule is realistic and has the desired effect, the teacher approves. If not, the teacher disapproves, forcing the student to avoid bad molecules and create good ones.”
ReLeaSE is a powerful innovation to virtual screening, the computational method widely used by the pharmaceutical industry to identify viable drug candidates. Virtual screening allows scientists to evaluate existing large chemical libraries, but the method only works for known chemicals. ReLeASE has the unique ability to create and evaluate new molecules.
“A scientist using virtual screening is like a customer ordering in a restaurant. What can be ordered is usually limited by the menu,” said Isayev. “We want to give scientists a grocery store and a personal chef who can create any dish they want.”
The team has used ReLeaSE to generate molecules with properties that they specified, such as desired bioactivity and safety profiles.The team used the ReLeaSE method to design molecules with customized physical properties, such as melting point and solubility in water, and to design new compounds with inhibitory activity against an enzyme that is associated with leukemia.
“The ability of the algorithm to design new, and therefore immediately patentable, chemical entities with specific biological activities and optimal safety profiles should be highly attractive to an industry that is constantly searching for new approaches to shorten the time it takes to bring a new drug candidate to clinical trials,” said Tropsha.
The Latest on: Drug design
via Google News
The Latest on: Drug design
- Center for Experimental Therapeutics aims to enable all steps of drug development on April 17, 2019 at 9:36 am
study design, how to conduct clinical trials and how to interact with stakeholders from the Food and Drug Administration, the National Institutes of Health and pharmaceutical companies involved in ... […]
- WPRO leads partner efforts to strengthen capacity towards scaling up programmatic response to drug-resistant TB on April 17, 2019 at 7:43 am
The workshop enabled the development of a reliable pool of competent next-generation specialists on drug resistant TB from across the Western ... Council also contributed significantly to the course ... […]
- Designer clothes-loving teenage drug dealer Lewis Bailey who had gold Rolex watch locked up on April 17, 2019 at 7:34 am
A TEENAGE drug dealer was caught with a large stash of cocaine and money as well as a gold Rolex watch and designer clothes. Lewis Bailey was busted by police who were looking for a wanted man at a ... […]
- AI for drug discovery will be driven by biopharma and the rise of Asian tigers, says Insilico CEO on April 17, 2019 at 6:09 am
Yet, the CEO of Insilico Medicine, a global biotech using AI for drug discovery and aging research ... in a zero-sum game framework – and domain expertise for small molecule design is going to be a ... […]
- Performance Enhancing Drug Use in Boxing on April 17, 2019 at 6:05 am
“In order to try to evade detection, athletes who continue to dope are having to resort to the use of a far more dangerous form of drug – the designer steroid,” writes Ray Kazlauskas in his September ... […]
- DNDi, Atomwise collaborate to advance drug development using AI for neglected diseases on April 17, 2019 at 4:43 am
“Our scientists are working creatively with DNDi researchers to apply our technology to targets that some might consider undruggable or too early for rational drug design due to insufficient data. ... […]
- The Access and Pricing Effect of Eliminating Drug Rebates on April 16, 2019 at 4:03 pm
Drug manufacturers that offer lower net prices through rebates ... Some contracts have been abandoned before completion due to the amount of work required to design and execute them. While VBCs ... […]
- Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS) on April 16, 2019 at 4:15 am
A drug program with Fast Track status is afforded ... FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. […]
- CVS CEO Larry Merlo on Rising Drug Prices on April 16, 2019 at 2:30 am
They discussed competition within drug classes, and why generic drugs may be the key ... year-over-year trend that was negative because they adopted many of the plan design offers. “Whether it was the ... […]
via Bing News